Citigroup’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $855K | Buy |
105,000
+70,000
| +200% | +$635K | ﹤0.01% | 3224 |
|
|
2025
Q4 | $235K | Buy |
+35,000
| New | +$264K | ﹤0.01% | 3925 |
|
|
2025
Q3 | – | Sell |
-27,300
| Closed | -$172K | – | 6242 |
|
|
2025
Q2 | $172K | Hold |
27,300
| – | – | ﹤0.01% | 4137 |
|
|
2025
Q1 | $175K | Sell |
27,300
-754,800
| -97% | -$6.24M | ﹤0.01% | 4275 |
|
|
2024
Q4 | $6.29M | Buy |
782,100
+80,900
| +12% | +$780K | ﹤0.01% | 1741 |
|
|
2024
Q3 | $8.86M | Sell |
701,200
-230,100
| -25% | -$2.97M | 0.01% | 1404 |
|
|
2024
Q2 | $11.8M | Buy |
+931,300
| New | +$9.37M | 0.01% | 1161 |
|
|
2024
Q1 | – | Sell |
-463,200
| Closed | -$2.22M | – | 5789 |
|
|
2023
Q4 | $2.22M | Sell |
463,200
-843,600
| -65% | -$5.16M | ﹤0.01% | 2146 |
|
|
2023
Q3 | $9.46M | Sell |
1,306,800
-19,100
| -1% | -$153K | 0.01% | 1135 |
|
|
2023
Q2 | $9.85M | Sell |
1,325,900
-861,800
| -39% | -$6.78M | 0.01% | 1150 |
|
|
2023
Q1 | $15.2M | Buy |
2,187,700
+1,030,200
| +89% | +$9.48M | 0.01% | 943 |
|
|
2022
Q4 | $11.9M | Buy |
1,157,500
+197,400
| +21% | +$3.48M | 0.01% | 1043 |
|
|
2022
Q3 | $17.5M | Buy |
960,100
+590,200
| +160% | +$25.6M | 0.01% | 849 |
|
|
2022
Q2 | $19M | Sell |
369,900
-1,201,200
| -76% | -$62.2M | 0.01% | 821 |
|
|
2022
Q1 | $116M | Buy |
1,571,100
+424,000
| +37% | +$37.8M | 0.07% | 250 |
|
|
2021
Q4 | $164M | Buy |
1,147,100
+1,126,300
| +5,415% | +$194M | 0.09% | 203 |
|
|
2021
Q3 | $4.31M | Buy |
+20,800
| New | +$4.58M | ﹤0.01% | 1926 |
|
|
2021
Q1 | – | Sell |
-34,700
| Closed | -$3.87M | – | 7041 |
|
|
2020
Q4 | $3.87M | Sell |
34,700
-19,500
| -36% | -$2.07M | ﹤0.01% | 2273 |
|
|
2020
Q3 | $5.87M | Buy |
54,200
+53,200
| +5,320% | +$6.48M | ﹤0.01% | 1783 |
|
|
2020
Q2 | $83K | Buy |
+1,000
| New | +$38.2K | ﹤0.01% | 5728 |
|
|
2020
Q1 | – | Sell |
-1,410
| Closed | -$6K | – | 7719 |
|
|
2019
Q4 | $6K | Sell |
1,410
-17,545
| -93% | -$76.1K | ﹤0.01% | 7354 |
|
|
2019
Q3 | $95K | Buy |
18,955
+16,355
| +629% | +$89.5K | ﹤0.01% | 5711 |
|
|
2019
Q2 | $15K | Buy |
2,600
+1,065
| +69% | +$8.38K | ﹤0.01% | 7192 |
|
|
2019
Q1 | $17K | Sell |
1,535
-2,330
| -60% | -$73.6K | ﹤0.01% | 7036 |
|
|
2018
Q4 | $142K | Buy |
3,865
+2,355
| +156% | +$91.3K | ﹤0.01% | 5354 |
|
|
2018
Q3 | $57K | Sell |
1,510
-5,225
| -78% | -$147K | ﹤0.01% | 6410 |
|
|
2018
Q2 | $180K | Buy |
6,735
+4,355
| +183% | +$147K | ﹤0.01% | 5172 |
|
|
2018
Q1 | $100K | Buy |
2,380
+445
| +23% | +$17.9K | ﹤0.01% | 5623 |
|
|
2017
Q4 | $48K | Buy |
1,935
+300
| +18% | +$7.32K | ﹤0.01% | 6217 |
|
|
2017
Q3 | $37K | Buy |
1,635
+30
| +2% | +$672 | ﹤0.01% | 6151 |
|
|
2017
Q2 | $37K | Sell |
1,605
-30
| -2% | -$589 | ﹤0.01% | 5984 |
|
|
2017
Q1 | $42K | Sell |
1,635
-2,690
| -62% | -$74K | ﹤0.01% | 5816 |
|
|
2016
Q4 | $109K | Sell |
4,325
-4,600
| -52% | -$134K | ﹤0.01% | 5721 |
|
|
2016
Q3 | $371K | Buy |
8,925
+5,505
| +161% | +$711K | ﹤0.01% | 4166 |
|
|
2016
Q2 | $497K | Buy |
3,420
+1,935
| +130% | +$222K | ﹤0.01% | 3674 |
|
|
2016
Q1 | $153K | Buy |
1,485
+45
| +3% | +$4.83K | ﹤0.01% | 5336 |
|
|
2015
Q4 | $242K | Sell |
1,440
-25
| -2% | -$3.85K | ﹤0.01% | 4560 |
|
|
2015
Q3 | $207K | Buy |
1,465
+1,215
| +486% | +$272K | ﹤0.01% | 4460 |
|
|
2015
Q2 | $56K | Buy |
+250
| New | +$43.9K | ﹤0.01% | 5446 |
|
|
2015
Q1 | – | Sell |
-9,000
| Closed | -$1.07M | – | 7349 |
|
|
2014
Q4 | $1.07M | Hold |
9,000
| – | – | ﹤0.01% | 3060 |
|
|
2014
Q3 | $751K | Buy |
+9,000
| New | +$813K | ﹤0.01% | 3226 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Citigroup's NVAX Position: Q1 2026 in Review
Citigroup reduced its Novavax (NVAX) stake by 42% in Q1 2026, selling an estimated $264K and leaving 40,854 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #3757.
Citigroup first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $62.9M in Q2 2022. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Citigroup held 40,854 shares of Novavax worth $333K as of Q1 2026.
- Citigroup sold 29,071 Novavax shares in Q1 2026, an estimated $264K.
- Novavax made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3757 holding.
- Citigroup first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Novavax position peaked at $62.9M in Q2 2022.
- 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.